\-\ Texto\\:\\ \ \(0\)\
\-\ no\\ significant\\ physical\\ exam\\ and\\ laboratory\\ findings\\.\ \(0\)\
\-\ laparoscopic\\ left\\ partial\\ nephrectomy\\ preformed\\ along\\ with\\ follow\\-up\\ imaging\\.\ \(0\)\
\-\ exophytic\\ mass\\ off\\ inferior\\ pole\\ of\\ left\\ kidney\\.\\ \\ the\\ solid\\,\\ heterogenous\\ mass\\ measures\\ 2\\.7\\ cm\\ in\\ diameter\\ and\\ disturbs\\ the\\ renal\\ contour\\.\\ \\ the\\ remainder\\ of\\ the\\ left\\ and\\ right\\ kidneys\\ is\\ normal\\.\\ \\ no\\ renal\\ vein\\ or\\ inferior\\ vena\\ cava\\ thromboses\\ are\\ present\\.\\ \\ there\\ is\\ no\\ adenopathy\\.\ \(0\)\
\-\ renal\\ cell\\ carcinoma\\.\ \(13\)\
\-\ 1\\.\\ \\ renal\\ cell\\ carcinoma\ \(0\)\
\-\ 2\\.\\ \\ renal\\ metastasis\ \(0\)\
\-\ 3\\.\\ \\ renal\\ adenoma\ \(0\)\
\-\ 4\\.\\ \\ oncocytoma\ \(0\)\
\-\ 5\\.\\ \\ renal\\ lymphoma\ \(0\)\
\-\ 6\\.\\ \\ renal\\ angiomyolipoma\ \(0\)\
\-\ 7\\.\\ \\ acute\\ focal\\ pyelonephritis\ \(0\)\
\-\ history\\ of\\ right\\ upper\\ quadrant\\ pain\\ for\\ the\\ past\\ two\\ weeks\\.\ \(0\)\
\-\ renal\\ cell\\ carcinoma\\,\\ the\\ most\\ common\\ primary\\ tumor\\ of\\ the\\ kidney\\,\\ is\\ found\\ incidentally\\ in\\ many\\ patients\\ with\\ the\\ widespread\\ use\\ of\\ cross\\-sectional\\ imaging\\.\\ \\ in\\ fact\\,\\ as\\ many\\ as\\ one\\-half\\ of\\ renal\\ cell\\ carcinomas\\ are\\ discovered\\ incidentally\\ at\\ early\\ stages\\ when\\ they\\ are\\ asymptomatic\\.\\ \\ ct\\ has\\ also\\ played\\ an\\ essential\\ role\\ in\\ staging\\ renal\\ cell\\ carcinoma\\ in\\ order\\ to\\ guide\\ prognosis\\ and\\ surgical\\ planning\\.\\ \\ the\\ patient\\ in\\ this\\ case\\ underwent\\ partial\\ nephrectomy\\ for\\ his\\ renal\\ cell\\ carcinoma\\.\\ \\ as\\ a\\ result\\,\\ this\\ case\\ generates\\ several\\ interesting\\ questions\\.\\ \\ what\\ is\\ the\\ standard\\ protocol\\ for\\ staging\\ renal\\ cell\\ carcinoma\\ with\\ ct\\?\\ \\ what\\ staging\\ systems\\ exist\\ for\\ renal\\ cell\\ carcinoma\\ and\\ what\\ are\\ their\\ differences\\?\\ \\ finally\\,\\ what\\ factors\\ determine\\ the\\ use\\ of\\ radical\\ nephrectomy\\ versus\\ nephron\\-sparing\\ surgical\\ techniques\\?\ \(0\)\
\-\ \\	\ \(2191\)\
\-\ once\\ a\\ renal\\ cell\\ carcinoma\\ is\\ suspected\\ incidentally\\,\\ there\\ is\\ a\\ standard\\ protocol\\ for\\ work\\-up\\ using\\ ct\\.\\ \\ first\\,\\ an\\ unenhanced\\ ct\\ is\\ preformed\\ to\\ use\\ as\\ a\\ baseline\\ once\\ intravenous\\ contrast\\ material\\ is\\ administered\\.\\ \\ due\\ to\\ a\\ significant\\ vascular\\ supply\\,\\ renal\\ cell\\ carcinomas\\ enhance\\ following\\ administration\\ of\\ contrast\\.\\ \\ 12\\ hu\\ of\\ enhancement\\ suggest\\ possible\\ malignancy\\.\\ \\ following\\ the\\ administration\\ of\\ contrast\\,\\ images\\ are\\ obtained\\ during\\ the\\ corticomedullary\\ phase\\,\\ nephrographic\\ phase\\,\\ and\\ excretory\\ phase\\.\\ \\ \ \(0\)\
\-\ \\ \\ \\ \\ \\ \\ \ \(1250\)\
\-\ the\\ corticomedullary\\ phase\\ occurs\\ between\\ 25\\ and\\ 70\\ seconds\\ after\\ injection\\ and\\ primarily\\ enhances\\ the\\ renal\\ cortex\\.\\ \\ while\\ not\\ perfect\\ for\\ detecting\\ small\\ lesions\\,\\ this\\ phase\\ can\\ aid\\ in\\ diagnosing\\ venous\\ extension\\ of\\ the\\ tumor\\.\\ \\ the\\ nephrographic\\ phase\\,\\ which\\ occurs\\ between\\ 80\\ and\\ 180\\ seconds\\ following\\ injection\\,\\ is\\ best\\ for\\ detecting\\ renal\\ masses\\ and\\ analyzing\\ indeterminate\\ lesions\\.\\ \\ finally\\,\\ the\\ excretory\\ phase\\ begins\\ 180\\ seconds\\ following\\ injection\\ and\\ helps\\ evaluate\\ the\\ collecting\\ system\\,\\ as\\ well\\ as\\ the\\ calices\\ and\\ renal\\ pelvis\\.\\ \\ \ \(0\)\
\-\ \\ \\ \\ \\ \\ \ \(1866\)\
\-\ \\ renal\\ cell\\ carcinoma\\ has\\ two\\ potential\\ staging\\ systems\\:\\ the\\ robson\\ classification\\ and\\ the\\ tmn\\ classification\\.\\ \\ ct\\ is\\ reported\\ to\\ be\\ 91\\%\\ accurate\\ in\\ staging\\ renal\\ cell\\ carcinoma\\.\\ \\ the\\ tmn\\ classification\\ is\\ considered\\ more\\ precise\\ because\\ of\\ its\\ clear\\ definition\\ of\\ the\\ anatomic\\ extent\\ of\\ the\\ tumor\\.\\ \\ with\\ respect\\ to\\ the\\ tmn\\ classification\\,\\ t1\\ is\\ reserved\\ for\\ tumors\\ less\\ than\\ 7\\ cm\\ and\\ t2\\ for\\ tumors\\ greater\\ than\\ 7\\ cm\\.\\ \\ t3\\ is\\ broken\\ down\\ into\\ three\\ groups\\ based\\ on\\ tumor\\ position\\.\\ \\ t3a\\ indicates\\ spread\\ to\\ the\\ perinephric\\ fat\\.\\ \\ t3b\\ indicates\\ that\\ the\\ tumor\\ is\\ present\\ in\\ the\\ renal\\ vein\\ only\\.\\ \\ t3c\\ describes\\ a\\ tumor\\ in\\ the\\ infradiaphragmatic\\ ivc\\.\\ \\ t4a\\ and\\ t4b\\ describe\\ tumors\\ with\\ direct\\ invasion\\ of\\ adjacent\\ organs\\ and\\ presence\\ in\\ the\\ supradiaphragmatic\\ ivc\\,\\ respectively\\.\\ \\ n1\\-3\\ are\\ reserved\\ for\\ regional\\ lymph\\ node\\ metastases\\ and\\ m1a\\-d\\ for\\ distant\\ metastases\\.\\ \\ \ \(0\)\
\-\ \\ \\ \\ \\ \ \(2733\)\
\-\ the\\ robson\\ classification\\ is\\ staged\\ i\\-iv\\.\\ \\ i\\ is\\ given\\ to\\ a\\ tumor\\ confined\\ within\\ the\\ renal\\ capsule\\.\\ \\ ii\\ indicates\\ spread\\ to\\ the\\ perinephric\\ fat\\.\\ \\ iiia\\ describes\\ the\\ presence\\ of\\ a\\ venous\\ thrombus\\,\\ whereas\\ iiib\\ describes\\ regional\\ lymph\\ node\\ metastases\\.\\ \\ iva\\ indicates\\ direct\\ invasion\\ of\\ adjacent\\ organs\\ and\\ ivb\\ indicates\\ distant\\ metastases\\.\\ \\ an\\ important\\ downfall\\ of\\ the\\ robson\\ classification\\ is\\ that\\ it\\ uses\\ stage\\ iii\\ to\\ describe\\ both\\ patients\\ with\\ venous\\ extension\\ alone\\ and\\ patients\\ with\\ regional\\ lymph\\ node\\ metastases\\.\\ \\ the\\ treatment\\ for\\ these\\ two\\ groups\\ of\\ patients\\ varies\\ significantly\\.\\ \\ venous\\ extension\\ of\\ the\\ tumor\\ can\\ be\\ treated\\ surgically\\,\\ whereas\\ lymph\\ node\\ metastases\\ indicate\\ a\\ need\\ for\\ palliative\\ therapy\\.\\ \\ \ \(0\)\
\-\ \\ \\ \\ \\ \\ \ \(1866\)\
\-\ due\\ to\\ the\\ rapid\\ increase\\ in\\ incidental\\ discovery\\ of\\ renal\\ cell\\ carcinoma\\,\\ many\\ tumors\\ are\\ small\\ in\\ size\\ and\\ early\\-stage\\.\\ \\ therefore\\,\\ nephron\\-sparing\\ surgery\\ is\\ often\\ an\\ option\\.\\ \\ the\\ procedure\\ consists\\ of\\ excision\\ of\\ the\\ renal\\ tumor\\ and\\ obtaining\\ 0\\.5\\ cm\\ margins\\ of\\ normal\\ renal\\ tissue\\ and\\ preserving\\ the\\ largest\\ amount\\ of\\ functioning\\ renal\\ parenchyma\\.\\ \\ this\\ procedure\\ is\\ particularly\\ desirable\\ when\\ radical\\ nephrectomy\\ would\\ lead\\ to\\ dialysis\\.\\ \\ therefore\\,\\ it\\ is\\ indicated\\ in\\ patients\\ with\\ a\\ solitary\\ functioning\\ kidney\\,\\ compromised\\ renal\\ function\\,\\ or\\ bilateral\\ tumors\\.\\ \\ in\\ addition\\,\\ data\\ indicates\\ that\\ small\\ \\<4\\ cm\\ in\\ diameter\\ lesions\\,\\ which\\ are\\ polar\\,\\ cortical\\,\\ and\\ a\\ safe\\ distance\\ away\\ from\\ the\\ renal\\ hilum\\ and\\ collecting\\ systems\\,\\ have\\ similar\\ survival\\ rates\\ for\\ the\\ nephron\\-sparing\\ procedure\\ and\\ radical\\ nephrectomy\\.\\ \\ the\\ size\\ and\\ position\\ of\\ the\\ patient\\â\\€\\™s\\ tumor\\ in\\ this\\ case\\ made\\ him\\ a\\ good\\ candidate\\ for\\ the\\ nephron\\-sparing\\ procedure\\.\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ renal\\:\\ 0\\.4595492984801837\ \(0\)\
\-\ the\\:\\ 0\\.2386465536607623\ \(0\)\
\-\ cell\\:\\ 0\\.18923867428327665\ \(0\)\
\-\ carcinoma\\:\\ 0\\.16743329141355107\ \(0\)\
\-\ indicates\\:\\ 0\\.16083556348842273\ \(0\)\
\-\ classification\\:\\ 0\\.15696573712308654\ \(0\)\
\-\ phase\\:\\ 0\\.1524236395422451\ \(0\)\
\-\ is\\:\\ 0\\.13937633868896326\ \(0\)\
\-\ and\\:\\ 0\\.1367157544917226\ \(0\)\
\-\ tumor\\:\\ 0\\.13310225138606416\ \(0\)\
\-\ nephrectomy\\:\\ 0\\.1299629904912686\ \(0\)\
\-\ staging\\:\\ 0\\.1299629904912686\ \(0\)\
\-\ of\\:\\ 0\\.12947618288118257\ \(0\)\
\-\ metastases\\:\\ 0\\.12343458508581918\ \(0\)\
\-\ tmn\\:\\ 0\\.11665929163126164\ \(0\)\
\-\ for\\:\\ 0\\.1156915754299824\ \(0\)\
\-\ robson\\:\\ 0\\.1128092770824749\ \(0\)\
\-\ in\\:\\ 0\\.1076163305624034\ \(0\)\
\-\ what\\:\\ 0\\.09787227284201624\ \(0\)\
\-\ seconds\\:\\ 0\\.09425666650884533\ \(0\)\
\-\ tumors\\:\\ 0\\.09357456561571026\ \(0\)\
\-\ node\\:\\ 0\\.08748855817561414\ \(0\)\
\-\ regional\\:\\ 0\\.08498036122203054\ \(0\)\
\-\ radical\\:\\ 0\\.08456854781792224\ \(0\)\
\-\ describes\\:\\ 0\\.08268050991832697\ \(0\)\
\-\ procedure\\:\\ 0\\.08115036797172326\ \(0\)\
\-\ lymph\\:\\ 0\\.07915115856626125\ \(0\)\
\-\ nephrographic\\:\\ 0\\.07777286108750775\ \(0\)\
\-\ are\\:\\ 0\\.07724764605679446\ \(0\)\
\-\ systems\\:\\ 0\\.07376110257229078\ \(0\)\
\-\ cm\\:\\ 0\\.0730723265815765\ \(0\)\
\-\ venous\\:\\ 0\\.07267195633318085\ \(0\)\
\-\ patients\\:\\ 0\\.07157647237211429\ \(0\)\
\-\ to\\:\\ 0\\.06997853042809761\ \(0\)\
\-\ excretory\\:\\ 0\\.06703111233805485\ \(0\)\
\-\ injection\\:\\ 0\\.06642775064840098\ \(0\)\
\-\ 180\\:\\ 0\\.06540445403842138\ \(0\)\
\-\ incidentally\\:\\ 0\\.06503865065205441\ \(0\)\
\-\ preformed\\:\\ 0\\.06469031942344856\ \(0\)\
\-\ corticomedullary\\:\\ 0\\.06341358517936947\ \(0\)\
\-\ as\\:\\ 0\\.061337629369577755\ \(0\)\
\-\ following\\:\\ 0\\.061062976213536214\ \(0\)\
\-\ many\\:\\ 0\\.06019012789368255\ \(0\)\
\-\ reserved\\:\\ 0\\.05922025051387818\ \(0\)\
\-\ detecting\\:\\ 0\\.05885603995445975\ \(0\)\
\-\ use\\:\\ 0\\.05841129614595239\ \(0\)\
\-\ describe\\:\\ 0\\.057844930518017625\ \(0\)\
\-\ groups\\:\\ 0\\.057531848578504546\ \(0\)\
\-\ carcinomas\\:\\ 0\\.056936833486762935\ \(0\)\
\-\ perinephric\\:\\ 0\\.056936833486762935\ \(0\)\
\-\ functioning\\:\\ 0\\.05637903187861482\ \(0\)\
\-\ finally\\:\\ 0\\.05488858874022\ \(0\)\
\-\ extension\\:\\ 0\\.05404026204119225\ \(0\)\
\-\ whereas\\:\\ 0\\.05401746614960311\ \(0\)\
\-\ kidney\\:\\ 0\\.05363221580941988\ \(0\)\
\-\ distant\\:\\ 0\\.05322388381680315\ \(0\)\
\-\ organs\\:\\ 0\\.05249515897820808\ \(0\)\
\-\ protocol\\:\\ 0\\.04966985813442253\ \(0\)\
\-\ ivc\\:\\ 0\\.04941851983064962\ \(0\)\
\-\ ct\\:\\ 0\\.048439441596044616\ \(0\)\
\-\ once\\:\\ 0\\.04783326262505992\ \(0\)\
\-\ collecting\\:\\ 0\\.04773011789527599\ \(0\)\
\-\ standard\\:\\ 0\\.04723155692951267\ \(0\)\
\-\ spread\\:\\ 0\\.04571876241469287\ \(0\)\
\-\ invasion\\:\\ 0\\.045397216993352994\ \(0\)\
\-\ two\\:\\ 0\\.04533532851027349\ \(0\)\
\-\ direct\\:\\ 0\\.044860974605739894\ \(0\)\
\-\ therefore\\:\\ 0\\.044860974605739894\ \(0\)\
\-\ lesions\\:\\ 0\\.04384339594894591\ \(0\)\
\-\ this\\:\\ 0\\.043720131272874704\ \(0\)\
\-\ diameter\\:\\ 0\\.040903060452543716\ \(0\)\
\-\ disturbs\\:\\ 0\\.040695194123096565\ \(0\)\
\-\ t4a\\:\\ 0\\.040695194123096565\ \(0\)\
\-\ t4b\\:\\ 0\\.040695194123096565\ \(0\)\
\-\ downfall\\:\\ 0\\.040695194123096565\ \(0\)\
\-\ position\\:\\ 0\\.04057518398586163\ \(0\)\
\-\ administration\\:\\ 0\\.040529312832081714\ \(0\)\
\-\ stage\\:\\ 0\\.040529312832081714\ \(0\)\
\-\ occurs\\:\\ 0\\.0401267519291217\ \(0\)\
\-\ with\\:\\ 0\\.03986262919064665\ \(0\)\
\-\ small\\:\\ 0\\.03937916335079247\ \(0\)\
\-\ partial\\:\\ 0\\.0392130134688098\ \(0\)\
\-\ an\\:\\ 0\\.038923295117647694\ \(0\)\
\-\ generates\\:\\ 0\\.038886430543753875\ \(0\)\
\-\ perfect\\:\\ 0\\.038886430543753875\ \(0\)\
\-\ analyzing\\:\\ 0\\.038886430543753875\ \(0\)\
\-\ t3a\\:\\ 0\\.038886430543753875\ \(0\)\
\-\ t3b\\:\\ 0\\.038886430543753875\ \(0\)\
\-\ t3c\\:\\ 0\\.038886430543753875\ \(0\)\
\-\ case\\:\\ 0\\.038352795237885984\ \(0\)\
\-\ calices\\:\\ 0\\.037603092360824965\ \(0\)\
\-\ supradiaphragmatic\\:\\ 0\\.037603092360824965\ \(0\)\
\-\ contrast\\:\\ 0\\.03709244324647606\ \(0\)\
\-\ early\\:\\ 0\\.0366859022221448\ \(0\)\
\-\ thromboses\\:\\ 0\\.03660765793129902\ \(0\)\
\-\ played\\:\\ 0\\.03660765793129902\ \(0\)\
\-\ infradiaphragmatic\\:\\ 0\\.03660765793129902\ \(0\)\
\-\ presence\\:\\ 0\\.036567729371921744\ \(0\)\
\-\ vein\\:\\ 0\\.03648011570788792\ \(0\)\
\-\ iva\\:\\ 0\\.03579432878148228\ \(0\)\
\-\ ivb\\:\\ 0\\.03579432878148228\ \(0\)\
\-\ preserving\\:\\ 0\\.03579432878148228\ \(0\)\
\-\ desirable\\:\\ 0\\.03579432878148228\ \(0\)\
\-\ iiia\\:\\ 0\\.03510666878355201\ \(0\)\
\-\ inferior\\:\\ 0\\.03462394199287513\ \(0\)\
\-\ polar\\:\\ 0\\.03451099059855337\ \(0\)\
\-\ size\\:\\ 0\\.03446023245007279\ \(0\)\
\-\ staged\\:\\ 0\\.03398556520213959\ \(0\)\
\-\ iiib\\:\\ 0\\.03398556520213959\ \(0\)\
\-\ that\\:\\ 0\\.03312905074016511\ \(0\)\
\-\ differences\\:\\ 0\\.0330903812809217\ \(0\)\
\-\ between\\:\\ 0\\.03306837506345943\ \(0\)\
\-\ adjacent\\:\\ 0\\.032989419506080475\ \(0\)\
\-\ precise\\:\\ 0\\.03234515971172428\ \(0\)\
\-\ questions\\:\\ 0\\.03201456702128041\ \(0\)\
\-\ guide\\:\\ 0\\.031706792589684736\ \(0\)\
\-\ fat\\:\\ 0\\.031659131377463255\ \(0\)\
\-\ broken\\:\\ 0\\.03141888883628178\ \(0\)\
\-\ safe\\:\\ 0\\.03141888883628178\ \(0\)\
\-\ discovery\\:\\ 0\\.031148444830718325\ \(0\)\
\-\ when\\:\\ 0\\.030742846343776945\ \(0\)\
\-\ indeterminate\\:\\ 0\\.03065227173504725\ \(0\)\
\-\ uses\\:\\ 0\\.03065227173504725\ \(0\)\
\-\ compromised\\:\\ 0\\.03065227173504725\ \(0\)\
\-\ exist\\:\\ 0\\.030205803441937722\ \(0\)\
\-\ obtaining\\:\\ 0\\.0299982795186501\ \(0\)\
\-\ widespread\\:\\ 0\\.029799981989299527\ \(0\)\
\-\ significant\\:\\ 0\\.029385003179668787\ \(0\)\
\-\ due\\:\\ 0\\.029254753862689012\ \(0\)\
\-\ helps\\:\\ 0\\.029253057949452686\ \(0\)\
\-\ varies\\:\\ 0\\.029253057949452686\ \(0\)\
\-\ accurate\\:\\ 0\\.029084699860525316\ \(0\)\
\-\ oncocytoma\\:\\ 0\\.028922465259008812\ \(0\)\
\-\ planning\\:\\ 0\\.028922465259008812\ \(0\)\
\-\ than\\:\\ 0\\.0288502916449095\ \(0\)\
\-\ diagnosing\\:\\ 0\\.02861469082741314\ \(0\)\
\-\ respect\\:\\ 0\\.02861469082741314\ \(0\)\
\-\ essential\\:\\ 0\\.028468416743381467\ \(0\)\
\-\ hu\\:\\ 0\\.028326787074010183\ \(0\)\
\-\ dialysis\\:\\ 0\\.02818951593930741\ \(0\)\
\-\ aid\\:\\ 0\\.02805634306844673\ \(0\)\
\-\ 91\\:\\ 0\\.02805634306844673\ \(0\)\
\-\ definition\\:\\ 0\\.02805634306844673\ \(0\)\
\-\ laparoscopic\\:\\ 0\\.027927030829482863\ \(0\)\
\-\ begins\\:\\ 0\\.027927030829482863\ \(0\)\
\-\ unenhanced\\:\\ 0\\.027801361677596406\ \(0\)\
\-\ candidate\\:\\ 0\\.027801361677596406\ \(0\)\
\-\ t3\\:\\ 0\\.027560169972775654\ \(0\)\
\-\ palliative\\:\\ 0\\.02744429437011\ \(0\)\
\-\ exophytic\\:\\ 0\\.027331352644484233\ \(0\)\
\-\ distance\\:\\ 0\\.027331352644484233\ \(0\)\
\-\ hilum\\:\\ 0\\.027331352644484233\ \(0\)\
\-\ angiomyolipoma\\:\\ 0\\.027221199890426866\ \(0\)\
\-\ stages\\:\\ 0\\.027221199890426866\ \(0\)\
\-\ confined\\:\\ 0\\.027221199890426866\ \(0\)\
\-\ techniques\\:\\ 0\\.027113701679666126\ \(0\)\
\-\ interesting\\:\\ 0\\.026906177756378505\ \(0\)\
\-\ baseline\\:\\ 0\\.026906177756378505\ \(0\)\
\-\ imaging\\:\\ 0\\.026746454497401897\ \(0\)\
\-\ role\\:\\ 0\\.02670788022702793\ \(0\)\
\-\ can\\:\\ 0\\.026707494087207764\ \(0\)\
\-\ rates\\:\\ 0\\.026518023494667493\ \(0\)\
\-\ pyelonephritis\\:\\ 0\\.02642604168173585\ \(0\)\
\-\ away\\:\\ 0\\.02642604168173585\ \(0\)\
\-\ administered\\:\\ 0\\.02633591821495828\ \(0\)\
\-\ respectively\\:\\ 0\\.02633591821495828\ \(0\)\
\-\ present\\:\\ 0\\.026115301048235746\ \(0\)\
\-\ it\\:\\ 0\\.026051864073720368\ \(0\)\
\-\ left\\:\\ 0\\.02604151693461262\ \(0\)\
\-\ indicate\\:\\ 0\\.025910743326852552\ \(0\)\
\-\ largest\\:\\ 0\\.025910743326852552\ \(0\)\
\-\ option\\:\\ 0\\.025673822526980677\ \(0\)\
\-\ supply\\:\\ 0\\.025597564945621657\ \(0\)\
\-\ consists\\:\\ 0\\.02530493810032344\ \(0\)\
\-\ him\\:\\ 0\\.02530493810032344\ \(0\)\
\-\ alone\\:\\ 0\\.025030330809457005\ \(0\)\
\-\ data\\:\\ 0\\.024964241306175132\ \(0\)\
\-\ capsule\\:\\ 0\\.02489911664768524\ \(0\)\
\-\ survival\\:\\ 0\\.024834929067211266\ \(0\)\
\-\ no\\:\\ 0\\.02482516432392904\ \(0\)\
\-\ surgical\\:\\ 0\\.02473608416663658\ \(0\)\
\-\ vena\\:\\ 0\\.024587034190763593\ \(0\)\
\-\ cava\\:\\ 0\\.02446806821050406\ \(0\)\
\-\ fact\\:\\ 0\\.024409754179105538\ \(0\)\
\-\ primarily\\:\\ 0\\.024409754179105538\ \(0\)\
\-\ particularly\\:\\ 0\\.02402159991739453\ \(0\)\
\-\ heterogenous\\:\\ 0\\.023968806876649183\ \(0\)\
\-\ significantly\\:\\ 0\\.02391663131252996\ \(0\)\
\-\ determine\\:\\ 0\\.023664532609908126\ \(0\)\
\-\ thrombus\\:\\ 0\\.023664532609908126\ \(0\)\
\-\ rapid\\:\\ 0\\.023664532609908126\ \(0\)\
\-\ anatomic\\:\\ 0\\.023615778464756335\ \(0\)\
\-\ surgically\\:\\ 0\\.023615778464756335\ \(0\)\
\-\ order\\:\\ 0\\.02351984014612998\ \(0\)\
\-\ need\\:\\ 0\\.023425921732395903\ \(0\)\
\-\ extent\\:\\ 0\\.02328865059769313\ \(0\)\
\-\ solitary\\:\\ 0\\.02328865059769313\ \(0\)\
\-\ has\\:\\ 0\\.023246839888732232\ \(0\)\
\-\ discovered\\:\\ 0\\.02319942842597436\ \(0\)\
\-\ intravenous\\:\\ 0\\.02319942842597436\ \(0\)\
\-\ which\\:\\ 0\\.023141952041404436\ \(0\)\
\-\ contour\\:\\ 0\\.022900496335982123\ \(0\)\
\-\ enhance\\:\\ 0\\.022778270611420907\ \(0\)\
\-\ potential\\:\\ 0\\.022738261734465623\ \(0\)\
\-\ lead\\:\\ 0\\.022659304631161375\ \(0\)\
\-\ versus\\:\\ 0\\.02250546318335006\ \(0\)\
\-\ enhances\\:\\ 0\\.022430487302869947\ \(0\)\
\-\ remainder\\:\\ 0\\.02239346667647523\ \(0\)\
\-\ prognosis\\:\\ 0\\.02239346667647523\ \(0\)\
\-\ pole\\:\\ 0\\.02217757164943943\ \(0\)\
\-\ iii\\:\\ 0\\.021971644633231095\ \(0\)\
\-\ kidneys\\:\\ 0\\.021905061906456174\ \(0\)\
\-\ margins\\:\\ 0\\.021711076566787297\ \(0\)\
\-\ important\\:\\ 0\\.02155562669643166\ \(0\)\
\-\ factors\\:\\ 0\\.021525176340121566\ \(0\)\
\-\ material\\:\\ 0\\.021435052873343997\ \(0\)\
\-\ adenopathy\\:\\ 0\\.021405411834866016\ \(0\)\
\-\ off\\:\\ 0\\.02126009084556681\ \(0\)\
\-\ their\\:\\ 0\\.021119354887483364\ \(0\)\
\-\ 70\\:\\ 0\\.021009877985238273\ \(0\)\
\-\ using\\:\\ 0\\.020929498155122933\ \(0\)\
\-\ indicated\\:\\ 0\\.020929498155122933\ \(0\)\
\-\ suspected\\:\\ 0\\.02085054105181869\ \(0\)\
\-\ normal\\:\\ 0\\.020779628541410973\ \(0\)\
\-\ measures\\:\\ 0\\.02074739287541372\ \(0\)\
\-\ cortex\\:\\ 0\\.020721974231835312\ \(0\)\
\-\ good\\:\\ 0\\.020696699604007374\ \(0\)\
\-\ suggest\\:\\ 0\\.020671567369204277\ \(0\)\
\-\ down\\:\\ 0\\.020671567369204277\ \(0\)\
\-\ parenchyma\\:\\ 0\\.020671567369204277\ \(0\)\
\-\ be\\:\\ 0\\.020645611093355956\ \(0\)\
\-\ function\\:\\ 0\\.020597009201152802\ \(0\)\
\-\ addition\\:\\ 0\\.020597009201152802\ \(0\)\
\-\ best\\:\\ 0\\.020475449639495588\ \(0\)\
\-\ increase\\:\\ 0\\.02042773838385839\ \(0\)\
\-\ amount\\:\\ 0\\.020357114852711227\ \(0\)\
\-\ adenoma\\:\\ 0\\.020287591992930815\ \(0\)\
\-\ there\\:\\ 0\\.020250515534971595\ \(0\)\
\-\ ii\\:\\ 0\\.02006337596456085\ \(0\)\
\-\ excision\\:\\ 0\\.02006337596456085\ \(0\)\
\-\ 80\\:\\ 0\\.0198498921741498\ \(0\)\
\-\ considered\\:\\ 0\\.01982909512073241\ \(0\)\
\-\ evaluate\\:\\ 0\\.01978778964156531\ \(0\)\
\-\ made\\:\\ 0\\.019626289294001315\ \(0\)\
\-\ solid\\:\\ 0\\.019508888837491255\ \(0\)\
\-\ mass\\:\\ 0\\.019440102221725354\ \(0\)\
\-\ system\\:\\ 0\\.019413361421078468\ \(0\)\
\-\ similar\\:\\ 0\\.0193944989833417\ \(0\)\
\-\ result\\:\\ 0\\.019050481787195397\ \(0\)\
\-\ malignancy\\:\\ 0\\.019050481787195397\ \(0\)\
\-\ incidental\\:\\ 0\\.018862803789861594\ \(0\)\
\-\ its\\:\\ 0\\.018829512889997967\ \(0\)\
\-\ greater\\:\\ 0\\.018747356610713996\ \(0\)\
\-\ metastasis\\:\\ 0\\.018650725542668077\ \(0\)\
\-\ laboratory\\:\\ 0\\.018478828413588125\ \(0\)\
\-\ clear\\:\\ 0\\.01844827377442189\ \(0\)\
\-\ based\\:\\ 0\\.01843307457784997\ \(0\)\
\-\ reported\\:\\ 0\\.018328105972985398\ \(0\)\
\-\ cortical\\:\\ 0\\.018269214558250868\ \(0\)\
\-\ they\\:\\ 0\\.018182309994080208\ \(0\)\
\-\ 25\\:\\ 0\\.018027253125211775\ \(0\)\
\-\ would\\:\\ 0\\.018013420680397418\ \(0\)\
\-\ obtained\\:\\ 0\\.01799963099436784\ \(0\)\
\-\ quadrant\\:\\ 0\\.01782413944437763\ \(0\)\
\-\ pelvis\\:\\ 0\\.017797743155062214\ \(0\)\
\-\ because\\:\\ 0\\.01778460335210599\ \(0\)\
\-\ or\\:\\ 0\\.017705073418938882\ \(0\)\
\-\ underwent\\:\\ 0\\.017529621961255668\ \(0\)\
\-\ given\\:\\ 0\\.017504907438881206\ \(0\)\
\-\ 12\\:\\ 0\\.01739535585184562\ \(0\)\
\-\ asymptomatic\\:\\ 0\\.017323788115608398\ \(0\)\
\-\ masses\\:\\ 0\\.017323788115608398\ \(0\)\
\-\ less\\:\\ 0\\.017311970996437564\ \(0\)\
\-\ possible\\:\\ 0\\.017241718207852707\ \(0\)\
\-\ first\\:\\ 0\\.017172554653769264\ \(0\)\
\-\ three\\:\\ 0\\.017081973676106893\ \(0\)\
\-\ along\\:\\ 0\\.017048474445756544\ \(0\)\
\-\ right\\:\\ 0\\.016873425855867537\ \(0\)\
\-\ vascular\\:\\ 0\\.016799677666846986\ \(0\)\
\-\ several\\:\\ 0\\.016695687879293715\ \(0\)\
\-\ often\\:\\ 0\\.016604125625250536\ \(0\)\
\-\ past\\:\\ 0\\.0165640268394972\ \(0\)\
\-\ patient\\:\\ 0\\.016553223114055615\ \(0\)\
\-\ found\\:\\ 0\\.016465329010972547\ \(0\)\
\-\ while\\:\\ 0\\.016445848805875476\ \(0\)\
\-\ during\\:\\ 0\\.01611803379913178\ \(0\)\
\-\ only\\:\\ 0\\.015897803499244214\ \(0\)\
\-\ t1\\:\\ 0\\.015855032702969445\ \(0\)\
\-\ treated\\:\\ 0\\.01584652753379944\ \(0\)\
\-\ primary\\:\\ 0\\.015647121829091445\ \(0\)\
\-\ his\\:\\ 0\\.015432954628510022\ \(0\)\
\-\ weeks\\:\\ 0\\.015250849348800808\ \(0\)\
\-\ focal\\:\\ 0\\.015221208310322825\ \(0\)\
\-\ lymphoma\\:\\ 0\\.01515522742152736\ \(0\)\
\-\ enhancement\\:\\ 0\\.01464681469577315\ \(0\)\
\-\ t2\\:\\ 0\\.014640326025715173\ \(0\)\
\-\ therapy\\:\\ 0\\.014620916452476962\ \(0\)\
\-\ common\\:\\ 0\\.014431328720018823\ \(0\)\
\-\ these\\:\\ 0\\.014369882020151718\ \(0\)\
\-\ both\\:\\ 0\\.014190462668363045\ \(0\)\
\-\ more\\:\\ 0\\.013973090853751742\ \(0\)\
\-\ physical\\:\\ 0\\.01379791409349583\ \(0\)\
\-\ acute\\:\\ 0\\.013765820718538619\ \(0\)\
\-\ surgery\\:\\ 0\\.013681350315354309\ \(0\)\
\-\ bilateral\\:\\ 0\\.013676123648232258\ \(0\)\
\-\ upper\\:\\ 0\\.013598449720509517\ \(0\)\
\-\ into\\:\\ 0\\.013527154323651348\ \(0\)\
\-\ tissue\\:\\ 0\\.01334889025501488\ \(0\)\
\-\ most\\:\\ 0\\.013243357250311708\ \(0\)\
\-\ exam\\:\\ 0\\.012810001457670172\ \(0\)\
\-\ have\\:\\ 0\\.01271214147504944\ \(0\)\
\-\ findings\\:\\ 0\\.012559084723026668\ \(0\)\
\-\ after\\:\\ 0\\.012344726908929453\ \(0\)\
\-\ well\\:\\ 0\\.012321532957831999\ \(0\)\
\-\ treatment\\:\\ 0\\.012121726960134492\ \(0\)\
\-\ also\\:\\ 0\\.01196951047495988\ \(0\)\
\-\ images\\:\\ 0\\.011770903124455702\ \(0\)\
\-\ within\\:\\ 0\\.01172007507881172\ \(0\)\
\-\ from\\:\\ 0\\.010106445046390362\ \(0\)\
\-\ not\\:\\ 0\\.010045845913460284\ \(0\)\
\-\ history\\:\\ 0\\.009722203564404248\ \(0\)\
\-\ at\\:\\ 0\\.009611630737849904\ \(0\)\
\-\ pain\\:\\ 0\\.009105850997061848\ \(0\)\
\-\ on\\:\\ 0\\.007685412150029514\ \(0\)\
